About Abide Therapeutics
Abide Therapeutics is a company based in San Diego (United States) founded in 2011 was acquired by Lundbeck in May 2019. Abide Therapeutics has raised $12.2 million across 2 funding rounds from investors including Lundbeck and Cardinal Partners. The company has 47 employees as of December 31, 2017. Abide Therapeutics operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter San Diego, United States
- Employees 47 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Abide Therapeutics
Abide Therapeutics has successfully raised a total of $12.2M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $10 million completed in February 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abide Therapeutics
Abide Therapeutics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Lundbeck and Cardinal Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in early stage companies in the US
|
Locked | Locked | Locked | |
|
Drugs for CNS disorders are developed and advanced.
|
Locked | Locked | Locked |
Investor details for Abide Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abide Therapeutics
Investment portfolio details for Abide Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abide Therapeutics
Detailed financials for Abide Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abide Therapeutics Comparisons
Peer comparison for Abide Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abide Therapeutics
Abide Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Developer of therapeutics for pain relief and inflammatory diseases
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
Detailed competitors of Abide Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abide Therapeutics
Complete news archive for Abide Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abide Therapeutics
Abide Therapeutics was founded in 2011.
Abide Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Abide Therapeutics is a funded company, having raised a total of $12.2M across 2 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Abide Therapeutics is 47.
Abide Therapeutics investigates serine hydrolase inhibitors for pain management. It uses a proprietary drug development platform to generate lead molecules for inhibition of serine hydrolase activity. Its lead candidate targets monoacylglycerol lipase, a type of serine hydrolase, in the endocannabinoid system. It mimics the analgesic effects of marijuana without affecting cognition and is currently in phase I clinical trials.
Abide Therapeutics's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Abide Therapeutics has 2 investors. Key investors include Lundbeck, and Cardinal Partners.